Matrix Metalloproteinases Cause Peritoneal Injury in Peritoneal Dialysis by Ichiro Hirahara et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
Matrix Metalloproteinases Cause 
Peritoneal Injury in Peritoneal Dialysis 
Ichiro Hirahara, Tetsu Akimoto, Yoshiyuki Morishita,  
Makoto Inoue, Osamu Saito, Shigeaki Muto and Eiji Kusano 
Division of Nephrology, Department of Internal Medicine, Jichi Medical University 
Japan 
1. Introduction 
Long-term peritoneal dialysis (PD) leads to peritoneal injury with functional decline, such as 
ultrafiltration loss. Peritoneal injury is often accompanied by histological changes, such as 
peritoneal fibrosis and sclerosis. These complications involve evident diffuse fibrous 
thickening and/or edema of the peritoneum, and chronic inflammation (epithelial to 
mesenchymal transition of mesothelial cells as well as migration and proliferation of 
polynuclear leucocytes, macrophages, and mesenchymal cells in the peritoneum). At worst, 
peritoneal injury leads to encapsulating peritoneal sclerosis (EPS), a serious complication of 
PD [1-6]. At early stage of EPS (preEPS stage), peritoneal effluent with signs of inflammation 
is often observed [2]. At advanced stages of EPS, the small intestine adheres and is 
encapsulated within a collagen rich thick peritoneum to form a cocoon-like mass. As a 
result, EPS is associated with clinical symptoms, such as loss of appetite, nausea, vomiting, 
and emaciation due to malnutrition, as well as symptoms of intestinal obstruction that 
include abdominal pain, diarrhea, constipation, or lowered peristaltic bowel sounds. The 
incidence of EPS is not high: it occurs in about 0.4%–3.3% of patients who undergo PD. 
However, EPS has a high mortality rate, about half of the patients with EPS die [2-5]. The 
causes of functional disorders of the peritoneum are believed to be fibrosis, sclerosis, 
inflammation, angiogenesis, and vasculopathy. Peritoneal injury is probably caused by 
multiple factors, such as infection with bacteria or fungi resulting in peritonitis [2, 5, 6]; 
antiseptics [7-11]; exogenous materials like particulates and plasticizers [7]; and continuous 
exposure to nonphysiological PD solutions having high concentrations of glucose and 
glucose degradation products (GDPs), low pH, and high osmolarity [2, 12, 13]. 
Administration of corticosteroids, tamoxifen, immunosuppressive agents, and total 
parenteral nutrition are effective in the early stage of EPS development [2-4, 6]. However, 
for advanced EPS, in which bowel adhesions have formed, the only effective therapeutic 
method is surgical dissection of the encapsulated peritoneum; this must be performed by 
skilled surgeons using specialized techniques [2-5, 7]. It is important to monitor peritoneal 
injury, and develop methods for an early diagnosis of  EPS. At present, major diagnostic 
methods for EPS include abdominal palpation (for identification of a mass) and finding 
clinical symptoms of bowel obstruction, like those found in the ileus [2]. However, these are 
not objective criteria and it is not rare that no typical symptoms are found even in advanced 
cases of EPS. Some physicians utilize diagnostic imaging methods for detection of EPS, such 
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as X-ray, computed tomography, and ultrasonography; however, these methods are not 
suitable for early diagnosis because they can detect only EPS in an advanced stage [2, 3, 6]. 
C-reactive protein (CRP) and interleukin-6 (IL-6) are often used as biochemical markers for 
inflammation [2, 6, 14, 15]. However, since their levels also increase during infectious 
peritonitis, they are inadequate to be used as definitive diagnostic markers that can 
differentiate EPS from infectious peritonitis [14]. As mentioned previously, corticosteroids 
and immunosuppressive agents have been employed as effective initial therapies for EPS [2-
4, 6]; however these drugs, compromise the immune system with the risk of aggravating 
symptoms when administered to patients with infectious peritonitis. Therefore, a method 
can differentiate EPS from infectious peritonitis is required for the early diagnosis of EPS.  
To perform PD safely, it is important to monitor  peritoneal injury that may progress to EPS 
and diagnose EPS at an early stage; it is then necessary to prevent peritoneal injury from 
developing into severe EPS. 
During tissue injury, such as sclerosis or fibrosis, tissue destruction and excessive 
remodeling occur. In such events, matrix metalloproteinases (MMPs) degrade components 
of the extracellular matrix (ECM) and play significant roles in regulating angiogenesis, 
epithelial to mesenchymal transition, and migration of cells that promote fibroplasias or 
inflammation. MMP-1, an interstitial collagenase, degrades types I, II, III, VII, and X 
collagen. MMP-2, a gelatinase, degrades gelatin, type IV collagen, fibronectin, laminin, 
proteoglycan, and elastin. MMP-3, a stromelysin, degrades proteoglycan, gelatin, 
fibronectin, laminin, elastin, and type IV collagen. MMP-9, a gelatinase, degrades gelatin, 
type IV collagen, proteoglycans, elastin, and entactin. Membrane-type MMP-1 (MT1-MMP) 
contains a C-terminal transmembrane domain that anchors to the plasma membrane and 
cleaves proMMP-2 to produce its active form on the cell surface. Tissue inhibitors of MMP 
(TIMPs) inhibit ECM degradation by MMPs and play important roles in the 
proteolytic/antiproteolytic balance. TIMP-2 inhibits the activity of MT-MMPs, but TIMP-1 
does not. MMP expression is enhanced in various tissues during inflammation, fibrosis and 
sclerosis. Increased serum levels of MMP-1 and MMP-3 in rheumatoid arthritis [16], MMP-1, 
MMP-8, and MMP-9 in cystic fibrosis [17], MMP-9 in chronic obstructive pulmonary disease 
[18], MMP-2, MMP-9, and TIMP-1 in acute coronary syndrome [19], MMP-9 and TIMP-1 in 
aortic sclerosis [20], MMP-2 in liver cirrhosis [21], MMP-2 and TIMP-1 in hepatic fibrosis 
[22], and MMP-2 in chronic kidney disease [23, 24] suggest a relationship between MMP 
levels and pathology of tissue injury. 
2. Production of MMP-2 in animal models of peritoneal injury 
MMP-2 production increases in animal models of peritoneal injury induced by stimuli such 
as antiseptics, exogenous materials, and GDPs. 
In rodent models of peritoneal injury, the development of EPS was analyzed by injecting the 
antiseptic chlorhexidine gluconate into the peritoneal cavity to induce inflammation [7-11]. 
In this model, MMP-2 levels in the peritoneal effluent and MMP-2 gene expression in the 
peritoneum correlated with changes in thickness of the peritoneum, inflammation, D/D0 
glucose levels, and net ultrafiltration. In another model, peritoneal injury was induced by 
injecting talc, an exogenous material, into the peritoneal cavity. MMP-2 levels in the 
peritoneal effluent and MMP-2 gene expression in the peritoneum increased with the 
development of peritoneal injury [7]. GDPs are generated in PD solutions during heat 
sterilization and storage, and contribute to the bioincompatibility of conventional PD 
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solutions. MMP-2 levels in the peritoneal effluent increased in models of peritoneal injury 
induced by methylglyoxal (MGO) or formaldehyde, both extremely toxic GDPs [12, 13]. In 
models of peritoneal injury induced by chlorhexidine gluconate and MGO, abdominal 
cocoons were often formed, while in models induced by talc and formaldehyde, adhesions 
of the peritoneum were observed [7-9, 11, 12]. In many animal models of peritoneal injury, 
MMP-2 levels in the peritoneal effluent correlated with changes in inflammation, thickness 
of the peritoneum, D/D0 glucose levels, and net ultrafiltration. Thus, peritoneal injury is 
caused by increased MMP-2 induced by various stimuli, such as antiseptics, exogenous 
materials, and GDPs in the PD solution. Therefore, MMP-2 may play an important role in 
the development of peritoneal injury leading to EPS. 
3. MMPs as peritoneal injury markers in clinical diagnosis 
Results of the peritoneal equilibration test (PET) performed clinically have shown that 
MMP-2, -3, and TIMP-1 levels in the peritoneal effluent correlate with peritoneal injury 
(Figure 1) [25, 26]. PET is the method most frequently used to estimate PD efficiency and 
peritoneal injury [2, 27]. MMP-3 levels are influenced by gender and etiology of end-stage 
renal disease [26] and TIMP-1 expression is known to be induced by various factors, such as 
IL-1, tumor necrosis factor-┙, and transforming growth factor-┚ [23]; however, MMP-2 is 
usually expressed constitutively. MMP-3 and TIMP-1 may therefore be more easily affected 
by various factors than MMP-2. The measured D/S ratios of MMP-3 were nearly equal to 
the predicted D/S ratios when MMP-3 was transported only from the circulation [26]. This 
result suggests that most MMP-3 in the peritoneal effluent may be transported from the 
circulation. In contrast, the measured D/S ratios of MMP-2 and TIMP-1 were significantly 
higher than those predicted [26]. In addition, the correlation coefficient between the 
drainage levels of MMP-2 and TIMP-1 was higher than that between the drainage levels of 
MMP-2 and MMP-3 [26]. The difference between the measured D/S ratio and the predicted 
ratio may be attributable to the local production of MMP-2 and TIMP-1 in the peritoneal 
tissue along with their transport from the circulation [28]. In addition, MMP-1 and TIMP-2 
were not detected in the peritoneal effluent of most patients. Therefore, MMP-1 and TIMP-2 
are unsuitable as markers for determining the extent of peritoneal injury. These results 
suggest that MMP-2 may be a more useful marker of peritoneal injury with increased solute 
transport than other MMPs or TIMPs.  
IL-6, hyaluronic acid, and cancer antigen (CA) 125 are often used as markers of peritoneal 
injury [2, 29]. In the study by Kaku et al., although the sample size was not sufficient for a 
statistically significant relationship, the correlation coefficient between the peritoneal solute 
transport rate and MMP-2 levels was higher than that for IL-6, hyaluronic acid, or CA125 
[15].  
MMP-2 and/or MMP-9 degrade the endothelial basal lamina and increase vascular 
permeability [30]. Swann et al. have also reported that an increase in the permeability of the 
blood-brain barrier is associated with an increase in MMP levels, which digests the 
endothelial basal lamina that forms the barrier [31]. In PD, the microvascular wall and 
probably the interstitial tissue are the main barriers for peritoneal fluid and solute transport. 
MMP-2 digests type IV collagen and laminin, which are the main basement membrane 
components of the microvascular wall and the mesothelial layer. Thus, injury to the 
basement membrane by MMP-2 may result in fast solute transport rates. Giebel et al. have 
reported that elevated MMP-2 or MMP-9 expression in the retina may facilitate an increase 
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in vascular permeability by degrading occludin, the tight junction protein of endothelial or 
epithelial cells [32]. Osada et al. have reported that MMP-2 was mainly observed around 
 
 
 
                                           (A)                                                                            (B) 
Fig. 1. Relationship between the peritoneal solute transport rate and MMP-2 levels in the 
peritoneal effluent. 
The peritoneal solute transport rate was assessed using PET. MMP-2 levels in the peritoneal 
effluent obtained from PET were analyzed by enzyme-linked immunosorbent assay. (A) 
D/P creatinine ratios versus MMP-2 levels. (B) D/D0 glucose ratios versus MMP-2 levels. 
the blood vessels in the peritoneal tissues from long-term PD patients [33]. In PD, 
destruction of the tight junction of endothelial cells by MMP-2 may result in 
hyperpermeability of the peritoneum. From these studies, it is apparent that MMP-2 may 
directly increase the permeability of the peritoneum by destruction of the basement 
membrane and tight junction of endothelial cells. 
A multi-center clinical study and a case report revealed markedly increased MMP-2 levels in 
peritoneal effluents of patients with moderate peritoneal injury with ascites  [2, 25, 34]. In 
addition, EPS was shown to develop in more than half the patients having MMP-2 levels of 
more than 600 ng/ml, although half of the patients had been treated with steroids [26]. On 
the other hand, MMP-2 levels in the effluents of patients with EPS tended to be lower than 
those of patients with moderate peritoneal injury [26]. In advance-stage of EPS, the 
inflammation is weak and then MMP-2 levels in the effluents may be decreased. These 
findings suggest that a change in MMP-2 levels may be used as indicator of peritoneal injury 
or progression to EPS. 
MMP-9 is hardly detected in the peritoneal effluent of patients without infectious peritonitis. 
However, in patients with infectious peritonitis, MMP-9 levels in the peritoneal effluent 
increased markedly with a slight increase in MMP-2 levels [25, 35, 36]. These findings 
suggest that peritoneal injury that may lead to EPS can be clearly distinguished from 
infectious peritonitis by analyzing MMP-2 and MMP-9 levels in the peritoneal effluent 
(Figure 2). Many biomarkers, such as IL-6 and CRP, increase during peritoneal injury and 
infectious peritonitis. Therefore, MMP-2 may be a useful indicator for peritoneal injury that 
can differentiate from infectious peritonitis. 
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Fig. 2. Analysis of the peritoneal effluent with gelatin zymography.  
Gelatinases in the peritoneal effluent were analyzed by gelatin zymography. Gelatinases 
were detected as unstained proteolytic bands in gel stained with Coomassie Brilliant Blue. 
Lane 1: MMP marker (Chemicon International, Inc., Temecula, CA, USA). Lane 2: Control 
patient. Lane 3: Patient with mild peritoneal injury. Lane 4: Patient with moderate peritoneal 
injury (preEPS). Lane 5: Patient with severe peritoneal injury (EPS). Lane 6: Patient with 
bacterial peritonitis. 
Minami et al. investigated the correlations between ┚2-microglobulin (┚2MG) and peritoneal 
injury biomarkers (e.g. hyaluronic acid, IL-6, MMP-2) in the peritoneal effluent obtained 
from a 7.5% icodextrin-based PD solution (ICO effluent) [37]. ┚2MG, hyaluronic acid, and 
MMP-2 levels in the ICO effluent were significantly higher than those in the 2.27% glucose-
based PD solution effluent. There was a trend toward higher IL-6 levels in the ICO effluent, 
although no significant differences were seen. There were positive correlations between the 
levels of various biomarkers and ┚2MG. Those authors proposed that subclinical injury of 
the peritoneum by ICO treatment may accelerate peritoneal permeability to increase ┚2MG 
in the effluent.  
Nishina et al. have reported that MMP-2 levels decreased in the peritoneal effluent and 
peritoneal function improved when conventional solutions (acidic pH and containing high 
levels of GDPs) were replaced with new PD solutions (neutral pH and containing low levels 
of GDPs) in high-transporter patients undergoing PD [38].   
Thus MMPs are possible markers of peritoneal injury that can differentiate from infectious 
peritonitis. A diagnostic method using peritoneal effluents enables easy sampling, is non-
invasive, and is not painful for patients. An MMP-9 test kit has been developed to diagnose 
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infectious peritonitis. This kit consists of an anti-MMP-9 antibody conjugated to a colloidal 
dye designed to detect MMP-9 in a nitrocellulose membrane dipstick assay based on 
immunochromatography [36, 39]. The diagnosis can be successfully completed within 10 
min. If such a test kit were developed for MMP-2, peritoneal injury could be monitored 
easily and rapidly at home. 
4. Production of MMP-2 in the peritoneum 
MMP-2 in the peritoneal tissue and effluent is considered to be primarily derived from 
activated cells in the peritoneum. 
Gene expression analysis and/or immunohistochemistry analysis revealed that MMP-2, 
MT1-MMP, and TIMP-2 are produced in the peritoneal tissue [7-13, 25]. MMP-2 is produced 
by peritoneal cells, such as macrophages, mesenchymal cells, endothelial cells, and 
mesothelial cells (Figures 3 and 4, Table). These peritoneal cells are activated by various 
stimuli, such as infectious peritonitis; exogenous materials like particulates; antiseptics; 
advanced glycation products; and GDPs and also the pH of the PD solution. These activated 
cells produce various cytokines, growth factors, and other mediators that induce peritoneal 
injury. Macrophages may infiltrate or migrate into the peritoneum while ECM is being 
degraded by MMP-2 produced by these cells [8, 12]. In cultured human mesothelial cells, the 
production of MMP-2 is upregulated by transforming growth factor-┚ and is decreased by 
thrombin [40-42]. Activated mesothelial cells transform to mesenchymal cells and then the 
epithelial-to-mesenchymal transition of mesothelial cells subsequently induces MMP-2 
production [13, 43]. Transformed mesothelial cells may invade the peritoneum while ECM is 
being digested by MMP-2 and upregulates the production of vascular endothelial growth 
factor that enhances angiogenesis, nitric oxide synthesis, and vascular permeability [25, 26]. 
 
 
Fig. 3. MMP-2 production in the peritoneum of rat models of peritoneal injury. 
MMP-2 production in the parietal peritoneum was immunohistologically analyzed using an 
anti-MMP-2 antibody. (A) The histological image of the parietal peritoneum of the talc-
treated rats. Mesenchymal cells, macrophages, and peritoneal mesothelial cells that produce 
MMP-2 are shown by shaded arrow heads, open arrow heads, and closed arrow heads, 
respectively. (B) The histological image of the parietal peritoneum of the chlorhexidine 
gluconate-treated rats. Macrophages and vascular endothelial cells are shown by open 
arrow heads and shaded arrow heads, respectively. 
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MMP-2-producing cells target of MMP-2 histological change 
macrophages 
mesenchymal cells (fibroblasts) 
mesothelial cells 
endothelial cell 
ECM 
ECM 
ECM, BM 
ECM, BM 
inflammation 
fibrosis, inflammation 
EMT 
angiogenesis 
ECM: extracellular matrix, BM: basement membrane, EMT: epithelial-to-mesenchymal transition 
Table 1. Tissue destruction by MMP-2 in the peritoneum 
 
Fig. 4. Tissue destruction by MMP-2 in the peritoneum.  
MMP-2 is assumed to destroy peritoneal tissue. Macrophages may infiltrate or migrate into 
the peritoneum while ECM is being degraded by the MMP-2 produced by these cells. 
Mesothelial cells may transform to mesenchymal cells (epithelial to mesenchymal transition: 
EMT) and infiltrate or migrate into the peritoneum, which is being digested by MMP-2. 
Activated mesenchymal cells synthesize ECM proteins that lead to peritoneal fibrosis or 
migrate during the disassemble of ECM of the peritoneum by MMP-2. Angiogenesis of 
capillaries may occur while ECM is being degraded by MMP-2 produced by activated 
endothelial cells.  
Del Peso et al. have reported that the transition of mesothelial cells to mesenchymal cells is 
an early event during PD and is associated with fast peritoneal transport [44], which may 
explain why drainage levels of MMP-2 reflects the peritoneal transport ratio. Activated 
mesenchymal cells, such as myofibroblasts or fibroblasts, synthesize ECM proteins or 
migrate during the disassemble of ECM of the peritoneum by MMP-2 or other proteinases 
[8-12, 33]. Presence of excessive ECM proteins, such as collagen, leads to peritoneal fibrosis 
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with peritoneal thickening and promotes the production of MMP-2 by myofibroblasts [9]. In 
addition, neomicrovascularization may occur while ECM is being degraded by MMP-2 
produced by activated endothelial cells in the microvasculature [10, 12, 33].  
According to the results of D/S ratio analysis, most MMP-2 in the peritoneal effluent is not 
transported from the circulation [26]. The measured D/S ratios of MMP-2 were higher than 
those predicted when MMP-2 was transported from the circulation only by diffusion.  
In summary, MMP-2 is produced by various peritoneal cells activated by a variety of 
stimuli. Because MMP-2 is produced primarily in the peritoneum, its drainage levels may 
indicate the condition of peritoneal injury. 
5. Protection from peritoneal injury by inhibition of MMP-2 
Peritoneal injury may be avoided by drugs that inhibit MMP-2 activity. Ro et al. have reported 
that the MMP inhibitor ONO-4817 controlled angiogenesis, infiltration of macrophage, and 
peritoneal fibrosis in rat models of peritoneal sclerosis [10], which suggests the possibility of 
protection from peritoneal injury by inhibition of MMP-2 activities.  
Angiotensin-converting enzyme (ACE) inhibitors have been shown to have inhibitory 
effects on MMP-2 activity [45, 46]. Yamamoto et al. have proposed a mechanism for the 
inhibitory specificity of ACE inhibitors against MMP-2 using three-dimensional models of 
the MMP-2-ACE inhibitor complex. Furthermore, these authors showed that ACE inhibitors 
directly inhibited MMP-2 activity in the peritoneal effluent from patients on PD [47]. In 
experimental animal models, use of ACE inhibitors protected the animals from peritoneal 
injury with fibrosis thickening and functional decline, such as increased solute transport [48-
50]. Sampimon et al. have reported the clinical possibility of a protective effect of ACE 
inhibitors on the development of EPS although it did not achieve statistical significance [51]. 
Thus, randomized controlled trials are needed to determine the level of protection gained 
against peritoneal injury using drugs, such as ACE inhibitors, that have an inhibitory effect 
on MMP-2 activity. 
6. Conclusions 
MMPs play critical roles in peritoneal injury. To perform PD safely, it is important to clarify 
the mechanisms by which MMPs cause peritoneal injury. MMP levels in the peritoneal 
effluent may be used as markers of peritoneal injury that can differentiate early EPS from 
infectious peritonitis. In addition, patients undergoing PD may be protected against 
peritoneal injury by controlling MMP activities. Future studies should examine the changes 
in MMP-2 levels with regard to progression of peritoneal injury to EPS and confirm the 
effects of MMPs inhibitors in controlling peritoneal injury 
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